Despite the ongoing financial market turbulence, TPG Capital has closed its $1.939 billion take-private buyout of Immucor (NASDAQ: BLUD). The firm paid Immucor stockholders $27 per share. Citi and J.P. Morgan provided debt financing in support of the transaction. Immucor manufactures reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion.
Since the beginning of 2008, PE investors have taken 22 public Healthcare companies private, according to the PitchBook Platform. With about $5.3 billion of capital already invested in the Healthcare industry this year though public-to-private buyouts, 2011 is closing in on the approximately $5.5 billion of capital invested in take-privates during all of last year.